Long-lasting sustained virological response in chronic hepatitis C previously treated with 40 kDa peginterferon alfa-2A (PEGASYS®): Mar Swain, University of Calgary, Calbary, AB Canada; E J Heathcote, Toronto Western Hospital, Toronto, ON Canada; Ming-Yang Lai, National Taiwan University Hospital, Taipei Taiwan; Vincent Bain, University of Alberta Hospital, Edmonton, AB Canada; Victor Feinman, University of Toronto, Toronto, ON Canada; Morris Sherman, Toronto General Hospital, Toronto, ON Canada; Kelly D Kaita, University of Manitoba, Winnipeg, MB Canada; Edward Gane, Auckland Hosp, Auckland New Zealand; Kevork Peltekian, Queen Elizabeth Hospital, Halifax, NS Canada; Karen Lindsay, University of Southern California, Los Angeles, CA; Joseph Hoffman, Michael Brunda, Hoffmann-La Roce, Nutley, NJ